Higher dementia risk seen in women with common health issue
An estimated 80% of women have some type of menopause symptoms — and the more symptoms they experience, the greater the chances of developing dementia later in life.
The findings were published in the journal PLOS One following a study by the University of Calgary.
The researchers analyzed the data of 896 postmenopausal women who participated in the Canadian Platform for Research Online to Investigate Health, Quality of Life, Cognition, Behaviour, Function, and Caregiving in Aging (CAN-PROTECT) study.
4 Key Women's Health Issues That Have Been Neglected, Expert Says
The women reported their perimenopausal symptoms to researchers. Their cognitive function was measured using the Everyday Cognition (ECog-II) Scale and the Mild Behavioral Impairment Checklist (MBI-C), with higher scores indicating greater severity.
Those with greater menopausal symptoms had higher scores for both cognitive tests, indicating more severe decline.
Read On The Fox News App
"One of the most interesting findings was the association between menopausal symptom burden and mild behavioral impairment (MBI) symptoms — a syndrome increasingly recognized as an early indicator of dementia risk," lead study author Zahinoor Ismail, M.D., professor of psychiatry, neurology, epidemiology and pathology at the University of Calgary, told Fox News Digital.
"These novel findings highlight the need to consider not only cognitive changes, but also mood, social interaction and personality changes that emerge and persist in later life following menopause."
While hormone therapy was not significantly associated with cognitive function, it was shown to have a significant link to fewer MBI symptoms, according to the researchers, emphasizing the need for further research into the potential role of hormone therapy in long-term brain health.
"Interestingly, participants who reported using estrogen-based hormone therapy during perimenopause had significantly lower mild behavioral impairment symptom severity," noted Ismail.
Alexa Fiffick, a board-certified family medicine physician specializing in menopause, stated that previous data has shown higher symptom burden is somehow related to decreased cognitive function and possibly dementia.
Some studies have shown that even when hot flashes aren't perceived by the woman, they are still associated with worsened cognitive function, according to the Ohio doctor.
Testosterone Therapy Could Help Boost Women's Sex Drive As They Age, But Risks Exist, Experts Say
"It is believed that the vasomotor symptoms are correlated with development of white matter hyperintensities in the brain, akin to what vascular dementia looks like on imaging," Fiffick, who was not involved in the new study, told Fox News Digital.
"We have yet to obtain the data that treating VMS will prevent cognitive decline, but are hopeful that with menopausal hormone therapy and other non-hormonal options, we may be able to obtain this data in the near future."
The researchers acknowledged several limitations of the study.
"This study is cross-sectional, meaning it captures a snapshot in time rather than tracking changes over the years," Ismail told Fox News Digital.
This means it can only identify associations between menopause symptoms and cognitive and behavioral health, but cannot determine whether the symptoms directly cause the changes in brain health.
Click Here To Sign Up For Our Health Newsletter
"To better understand the long-term impact of menopause on dementia risk, future research should follow participants over time and incorporate biological data, such as hormone levels and brain-related biomarkers (we are, in fact, doing this now)," Ismail added.
The study also did not assess the severity of the symptoms, which could play a key role in understanding risk.
Another limitation is that the study focused on the most commonly reported menopause symptoms, but it's possible that some participants experienced additional symptoms.
"In fact, it's reported that there may be 30+ symptoms that females may experience when undergoing the menopause transition," said Ismail. "While we included an 'other symptoms' category, it may not fully reflect the range of experiences."
The study also did not distinguish between different types and formulations of hormone therapy.
"Future studies will be able to explore whether specific types of HT have different effects on brain health," Ismail noted.
Tamsen Fadal, a New York menopause expert and author of the upcoming book "How to Menopause: Take Charge of Your Health, Reclaim Your Life, and Feel Even Better than Before," said she was not surprised by the results of the study.
"Research has been pointing to this connection for a while," she told Fox News Digital. "Brain scans of women in menopause reveal real structural and metabolic changes, and this study reinforces that we can't just brush these symptoms off as 'normal aging.'"
For more Health articles, visit www.foxnews.com/health
"For too long, women have been experiencing brain fog, memory lapses and mood changes, and many of us have been dismissed," Fadal went on.
"This research just reinforces that menopause is a neurological shift as much as it is a hormonal one."Original article source: Higher dementia risk seen in women with common health issue
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fox News
2 hours ago
- Fox News
Reagan-nominated federal judge accuses Trump admin of 'discrimination' with cuts to NIH diversity grants
Print Close By Alex Nitzberg Published June 17, 2025 A federal judge declared the Trump administration's move to nix some National Institutes of Health grants as illegal, describing the cuts as discriminatory during remarks on Monday, according to reports. "I am hesitant to draw this conclusion — but I have an unflinching obligation to draw it — that this represents racial discrimination and discrimination against America's LGBTQ community," Judge William Young said, according to Politico. "That's what this is. I would be blind not to call it out. My duty is to call it out." Young, who serves in the U.S. District Court for the District of Massachusetts, was nominated by then-President Ronald Reagan in 1985, according to the court's website. SECOND FEDERAL JUDGE SIDES AGAINST TRUMP'S ELECTION EXECUTIVE ORDER "Any discrimination by our government is so wrong that it requires the court to enjoin it and at an appropriate time, I'm going to do it," the judge said, according to Reuters. HHS Communications Director Andrew Nixon noted in a statement that the department "is exploring all legal options, including filing an appeal and moving to stay the order." WATCH: RFK JR. REBUKES DEM SENATOR FOR PLAYING POLITICS WITH CANCER-STRICKEN CONSTITUENT: 'YOU DON'T CARE' "HHS stands by its decision to end funding for research that prioritized ideological agendas over scientific rigor and meaningful outcomes for the American people," Nixon declared in the statement the department provided to Fox News Digital. "Under the leadership of Secretary Kennedy and the Trump administration, HHS is committed to ensuring that taxpayer dollars support programs rooted in evidence-based practices and gold standard science – not driven by divisive DEI mandates or gender ideology," Nixon said. White House Spokesman Kush Desai accused the judge of airing his own view. "It is appalling that a federal judge would use court proceedings to express his political views and preferences. How is a judge going to deliver an impartial decision when he explicitly stated his biased opinion that the Administration's retraction of illegal DEI funding is racist and anti-LGBTQ? Justice ceases to be administered when a judge clearly rules on the basis of his political ideologies," Desai declared in a statement he provided to Fox News Digital. WE GOT RID OF ALL THE BEAGLE EXPERIMENTS ON THE NIH CAMPUS, SAYS DR. JAY BHATTACHARYA CLICK HERE TO GET THE FOX NEWS APP The White House deputy press secretary asserted, "DEI is based on the premise that an individual's competence and abilities are tied to his or her racial background, and Americans have resoundingly rejected this flawed and racist logic." "The Trump administration is committed to restoring the Gold Standard of Science, and that starts with recognizing the biological reality of the male and female sexes. The NIH is focusing on Making America Healthy Again by realigning our research spending to address our chronic disease crisis instead, not to validate ideological activism," he noted. Print Close URL
Business Upturn
a day ago
- Business Upturn
Can-Fite to Present Phase IIa Pancreatic Cancer Study Progress During Partnering Meetings at the 2025 BIO International Convention in Boston
Ramat Gan, Israel, June 16, 2025 (GLOBE NEWSWIRE) — Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs for the treatment of cancer and inflammatory diseases, today announced that Dr. Sari Fishman, Vice President of Business Development, will present an update on the Company's ongoing Phase IIa study in pancreatic cancer during partnering meetings at the 2025 BIO International Convention, taking place June 16–19 in Boston, MA (link). The Phase IIa clinical trial is open-label study evaluating Namodenoson in patients with advanced pancreatic adenocarcinoma whose disease has progressed following at least one prior line of therapy. The study is assessing the safety, clinical activity, and pharmacokinetics (PK) of Namodenoson, administered orally at a dose of 25 mg twice daily in continuous 28-day cycles. Approximately 20 evaluable patients are expected to be enrolled. The trial is led by Prof. Salomon Stemmer, a prominent Oncologist and Key Opinion Leader at the Davidoff Center, Rabin Medical Center, Israel. Namodenoson has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer. 'We are pleased to report that 50% of the planned patient cohort has already been enrolled and that Namodenoson has demonstrated a favourable safety profile,' stated Prof. Salomon Stemmer. 'There is a critical unmet need for safe and effective treatment options for patients with advanced pancreatic cancer who have exhausted standard therapies. This study gives us the opportunity to advance a novel therapeutic approach for this challenging disease, stated Dr. Sari Fishman, VP of Business Development at Can-Fite.' Can-Fite looks forward to engaging with potential partners and collaborators at BIO 2025 as it continues to progress its clinical pipeline. About Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The Company's lead drug candidate, Piclidenoson recently reported topline results in a Phase 3 trial for psoriasis and commenced a pivotal Phase 3 trial. Can-Fite's liver drug, Namodenoson, is being evaluated in a Phase III trial for hepatocellular carcinoma (HCC), a Phase 2b trial for the treatment of MASH, and in a Phase 2a study in pancreatic cancer. Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,600 patients in clinical studies to date. For more information please visit: Forward-Looking Statements This press release may contain forward-looking statements, about Can-Fite's expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. All statements in this communication, other than those relating to historical facts, are 'forward looking statements'. Forward-looking statements can be identified by the use of forward-looking words such as 'believe,' 'expect,' 'intend,' 'plan,' 'may,' 'should' or 'anticipate' or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. For example, the Company is using forward-looking statements when it discusses the completion of the offerings, the satisfaction of customary closing conditions related to the offerings and the intended use of proceeds therefrom. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause Can-Fite's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results, performance or achievements to differ materially from those anticipated in these forward-looking statements include, among other things, our market and other conditions, history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; risks related to not satisfying the continued listing requirements of NYSE American; and statements as to the impact of the political and security situation in Israel on our business. More information on these risks, uncertainties and other factors is included from time to time in the 'Risk Factors' section of Can-Fite's Annual Report on Form 20-F filed with the SEC on April 14, 2025 and other public reports filed with the SEC and in its periodic filings with the TASE. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Can-Fite undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. Contact Can-Fite BioPharma Motti Farbstein [email protected] +972-3-9241114 Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Yahoo
a day ago
- Yahoo
Measles is surging in Alberta. Which vaccine-preventable disease could be next?
Doctors and scientists worry Alberta's measles outbreaks could signal the start of a new era when other dangerous infectious diseases of the past could re-emerge and pose new health threats. The province is battling its worst wave of measles cases in nearly half a century and there is no end in sight. The virus was declared eliminated in Canada in 1998. But vaccination rates have declined in Alberta, and around the country in recent years. "To some extent measles is the canary in the coalmine," said Dr. Cora Constantinescu, a pediatric infectious diseases specialist at Alberta Children's Hospital in Calgary. As of Friday, a total of 879 measles cases had been reported in the province since the outbreaks began in March. "When the immunization rates go down and you have a lot of unprotected people in the communities, usually the first vaccine-preventable disease to come back is measles," said Constantinescu on a measles episode of CBC Radio's Alberta at Noon. It's one of the first to re-emerge, experts say, because it is so highly contagious and requires very high vaccination rates (about 95 per cent) for population level protection. Provincial data shows in 2024 just 68.1 per cent of Alberta two-year-olds were up to date with two doses of the measles vaccine. The level of immunization needed for herd immunity varies from one disease to another, but vaccination rates for other childhood illnesses are dropping too, sparking fears about what's next. "For many diseases we have now fallen, again, below herd immunity," said Craig Jenne, a professor in the department of microbiology, immunology and infectious diseases at the University of Calgary. "We're getting into the realm where diseases that were really problematic here in Canada in the 1950s and 60s — and that through a really comprehensive and well-co-ordinated vaccination campaign were largely eliminated — are coming back." It's a big concern for University of Alberta infectious diseases specialist Dr. Lynora Saxinger as well. "To me it's a little bit of a red flag in terms of what we might be seeing of other diseases of the past. Maybe it won't be so much in the past anymore," she said. "And that is a large burden of illness that can have complications in a lot of different ways." These diseases, while often forgotten, can be life-changing and even deadly. "We worry about seeing resurgence of things like polio, that we really have not had for a long time," said Dr. Stephanie Smith, an infectious diseases specialist at the University of Alberta Hospital. Polio is highly infectious and can infect the nervous system. While many people have mild flu-like symptoms, or no symptoms at all, they can still spread the illness. And in some cases it can lead to paralysis and even death. "We've all seen the historic pictures of people in iron lungs to support breathing. There's no reason why that couldn't happen again if we see polio re-establish in the province," said Jenne. Polio outbreaks spread unfettered across the country for decades. In 1953 — a particularly bad year for the virus — there were 9,000 cases and 500 deaths reported. According to the Public Health Agency of Canada (PHAC) widespread immunization led to a dramatic drop in polio cases in the 1950s. The last time wild poliovirus was acquired in Canada was 1977 and the country was declared free of the wild poliovirus in 1994. Alberta's routine childhood immunization schedule recommends babies receive doses of the vaccine that protects against polio (IPV) at two months of age, four months, six months and 18 months. An additional dose is offered at the age of four. The injections also protect against diptheria, tetanus, and pertussis (DTaP). Provincial data shows 75.8 per cent of two-year-olds were up to date with four doses of the vaccine in 2015. That number dropped to 68.9 per cent in 2024. According to Jenne, polio vaccine uptake needs to be at least 80 to 86 per cent for herd immunity. In 2024, the north, central and south zones had the lowest rates, hovering between 55 and 56 per cent. In some localized areas the uptake is extremely low. In High Level, for example, 13.4 per cent of two-year-olds had four doses of the polio vaccine in 2024. Two Hills County reported 17.3 per cent and the Municipal District of Taber reported 28.7 per cent. "[With] polio and all sorts of other vaccine-preventable illnesses, it's concerning that we see vaccination rates being low for all of those," said Smith. Pertussis, which is also known as whooping cough, has already flared up in Alberta. "Whooping cough is very dangerous for infants under the age of one," said Jenne. Pertussis can lead to serious complications in young babies including pneumonia, seizures and death. Vaccination rates for it have fallen alongside polio. "One to four deaths related to pertussis occur each year in Canada, typically in infants who are too young to be immunized, or children who are unimmunized or only partially immunized," the PHAC website states. There were 894 confirmed cases of pertussis in Alberta in 2023, when outbreaks were declared in all health zones. And outbreaks have since continued. "It is a changing landscape now where unfortunately the advantage is tipping in favour of these infectious diseases," said Jenne. Doctors worry about mumps and chicken pox as well. Saxinger said Alberta's overall vaccination rates tend to be lower than many other jurisdictions and she wants people to know these are not just benign childhood illnesses. "There is genuinely a lot of concern around the whole vaccine-preventable disease front," she said. "We're not thinking about people who had complications along the way and the burden of that in a community." And as doctors and scientists watch Alberta's measles case counts balloon, that sense of urgency grows. "We have tools to bring them back under control. It just requires significant effort — significant co-ordination — and we need the public to step up and get those vaccine rates back up to the protection that we had enjoyed for the last two or three decades that really saw these diseases eradicated from Canada," said Jenne.
